Amgen Fremont Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Abgenix, Inc. (to 2006)
5
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 29, 2027The maintenance fee for Human Monoclonal Antibodies to Activin Receptor-Like KINASE-1 (US 9,221,915) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Jul 19, 2027The maintenance fee for Nucleic Acids Encoding Antibodies to CCR2 (US 9,238,691) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Human Antibodies That Bind Human Madcam (US 9,328,169) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 23, 2026
- Oct 2 US 8,101,178 Antibodies directed to tumor necrosis factor and uses thereof · term ended
- Sep 30 US 7,537,762 Human Monoclonal Antibodies to Activin Receptor-Like KINASE-1 · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE45,847 | Antibodies to Madcam In force · Low confidence | In force | Low confidence | |
| US 8,080,646 | Human Monoclonal Antibodies to Activin Receptor-Like KINASE-1 In force · High confidence | In force | High confidence | |
| US 7,585,500 | Fully Human Monoclonal Antibodies to IL-13 In force · High confidence | In force | High confidence | |
| US 9,221,915 | Human Monoclonal Antibodies to Activin Receptor-Like KINASE-1 In force · High confidence | In force | High confidence | |
| US 9,238,691 | Nucleic Acids Encoding Antibodies to CCR2 In force · High confidence | In force | High confidence | |
| US 9,328,169 | Human Antibodies That Bind Human Madcam In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 3 patents in force now held by others · 37 lapsed for an unpaid fee · 67 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 abandoned · 9 no status recorded